Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04590196 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients
A Early Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT04590196 is a Early Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 10 participants.
The verdict
NCT04590196, a Early Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Nutrition plays an important role in preventing progression of dry age related macular degeneration (AMD), a disease of aging that leads to drusen deposits in the macula causing significant decrease in vision. Drusen contains amyloid protein which is inhibited by curcumin, a natural plant based antioxidant. Oral Longvida curcumin has been shown to accumulate in the retina of human subjects within 10 days of supplementation. This study aims to investigate the duration of oral curcumin supplementation needed to see clinical impact in reducing volume and number of drusen and decreasing choriocapillaris density loss or flow impairment in dry AMD patients. Patients will be given a 12-month course of oral Longvida curcumin and clinical impact will be measured by multimodal retinal imaging (fundus photos, OCT and OCT-A) at day 0, month 3, month 6, and month 12 of supplementation. Previous small studies have shown change in drusen size within 4 6months of curcumin supplementation, given that drusen can naturally fluctuate in size, we want to have a longer study period with a control group to better understand the effects of curcumin on drusen characteristics.
Interventions
- OTHER placebo
- DRUG Longvida curcumin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2023-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04590196
The ClinicalTrials.gov registry entry for NCT04590196 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT04590196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04590196 about?
NCT04590196 is a clinical study titled "Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients". Nutrition plays an important role in preventing progression of dry age related macular degeneration (AMD), a disease of aging that leads to drusen deposits in the macula causing significant decrease in vision. Drusen contains amyloid protein which is inhibited by curcumin, a natural plant based anti...
What is the current status of trial NCT04590196?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2020-11-01. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT04590196?
The interventions under investigation include: placebo (OTHER), Longvida curcumin (DRUG).
Who is sponsoring clinical trial NCT04590196?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.